A new treatment option for the very rare condition infantile onset 5q spinal muscular atrophy (type I SMA) is among five medicines that have been endorsed by Scottish cost regulators for use on the NHS.
Read More
Cost regulators for NHS therapies in England and Wales have now published final guidelines backing the use of LEO Pharma’s Kyntheum as an option for treating severe plaque psoriasis.
Read More
Patients with severe plaque psoriasis are a step closer to getting NHS funded access to LEO Pharma’s Kyntheum, after cost regulators published final draft guidelines backing the drug.
Read More
The latest batch of decisions by the Scottish Medicines Consortium has given patients with certain forms of breast cancer, Gaucher disease and erectile dysfunction new treatment options on the NHS.
Read More
A new treatment option has been approved in the European Union for patients with psoriasis, paving the way for access to a novel approach for those with moderate-to-severe forms of the disease who are candidates for systemic therapy.
Read More
The US Food and Drug Administration has issued a green light for Valeant to market Siliq as a treatment for adults with moderate-to-severe plaque psoriasis, but with a boxed warning on suicide and a restricted prescriber programme.
Read More
Valeant’s skin jab brodalumab has taken a big step towards US approval after regulatory advisors backed the drug for adult patients with moderate-to-severe plaque psoriasis.
Read More
LEO Pharma has entered a strategic partnership with AstraZeneca for new medicines for atopic dermatitis and psoriasis, major skin diseases with a significant unmet medical need.
Read More
